107 related articles for article (PubMed ID: 12855619)
1. A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Hao D; Hammond LA; Eckhardt SG; Patnaik A; Takimoto CH; Schwartz GH; Goetz AD; Tolcher AW; McCreery HA; Mamun K; Williams JI; Holroyd KJ; Rowinsky EK
Clin Cancer Res; 2003 Jul; 9(7):2465-71. PubMed ID: 12855619
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
[TBL] [Abstract][Full Text] [Related]
3. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
9. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
14. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
15. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]